Pluri

Pluri company information, Employees & Contact Information

Explore related pages

Related company profiles:

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.

Company Details

Employees
254
Founded
-
Address
Matam Park, Bldg #5, Haifa,31905,israel
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Haifa
Looking for a particular Pluri employee's phone or email?

Pluri Questions

News

Pluristem Therapeutics Inc. Changes its Name to “Pluri - GlobeNewswire

Pluristem Therapeutics Inc. Changes its Name to “Pluri GlobeNewswire

FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome - BioInformant

FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome BioInformant

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture - Nasdaq

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture Nasdaq

Peripheral arterial disease (PAD) – A challenging manifestation of atherosclerosis - ScienceDirect.com

Peripheral arterial disease (PAD) – A challenging manifestation of atherosclerosis ScienceDirect.com

Pluristem reports topline results from Covid-19 therapy trial - Clinical Trials Arena

Pluristem reports topline results from Covid-19 therapy trial Clinical Trials Arena

NASA-partnered Pluristem crashes to Earth as it axes leading therapy - Fierce Biotech

NASA-partnered Pluristem crashes to Earth as it axes leading therapy Fierce Biotech

Independent Study Shows Use of PLX-PAD Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury | Newswise - Newswise

Independent Study Shows Use of PLX-PAD Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury | Newswise Newswise

Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US - Labiotech.eu

Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US Labiotech.eu

Pluristem stock soars to 52-week high, hits $6.63 - Investing.com

Pluristem stock soars to 52-week high, hits $6.63 Investing.com

Israeli COVID-19 treatment shows 100% survival rate - preliminary data - The Jerusalem Post

Israeli COVID-19 treatment shows 100% survival rate - preliminary data The Jerusalem Post

Hedge Funds Nibbling On Pluristem Therapeutics Inc. (PSTI) - Yahoo Finance

Hedge Funds Nibbling On Pluristem Therapeutics Inc. (PSTI) Yahoo Finance

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform - PR Newswire UK

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform PR Newswire UK

FDA clears Pluristem radiation treatment for emergency use - Reuters

FDA clears Pluristem radiation treatment for emergency use Reuters

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform - GlobeNewswire

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform GlobeNewswire

Pluristem Therapeutics, Interview with Yaky Yanay, President and Co-CEO - BioInformant

Pluristem Therapeutics, Interview with Yaky Yanay, President and Co-CEO BioInformant

Pluristem’s cell therapies head for orbit with NASA deal - Fierce Biotech

Pluristem’s cell therapies head for orbit with NASA deal Fierce Biotech

Pluristem Receives Approval for Grant from the Israel - GlobeNewswire

Pluristem Receives Approval for Grant from the Israel GlobeNewswire

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use - BioInformant

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use BioInformant

Pluristem Lands $27 Million in Non-Dilutive Funding for its Advanced-Stage Cell Therapies - BioInformant

Pluristem Lands $27 Million in Non-Dilutive Funding for its Advanced-Stage Cell Therapies BioInformant

Pluristem Gets Accelerated Approval Pathways in Top 3 Healthcare Markets – U.S., Europe, Japan - BioInformant

Pluristem Gets Accelerated Approval Pathways in Top 3 Healthcare Markets – U.S., Europe, Japan BioInformant

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents - BioInformant

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents BioInformant

Umbilical cord stem cells have the potential to treat COVID-19 - Open Access Government

Umbilical cord stem cells have the potential to treat COVID-19 Open Access Government

Israel's Tnuva partners with Pluristem to develop cultured cell-based meat - The Jerusalem Post

Israel's Tnuva partners with Pluristem to develop cultured cell-based meat The Jerusalem Post

Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project - drugdiscoverytrends.com

Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project drugdiscoverytrends.com

Former United Therapeutics CEO joins Pluristem strategic advisory board - The Jerusalem Post

Former United Therapeutics CEO joins Pluristem strategic advisory board The Jerusalem Post

Israeli companies at NASDAQ want to bring lab-grown meat to the masses - Jewish Telegraphic Agency

Israeli companies at NASDAQ want to bring lab-grown meat to the masses Jewish Telegraphic Agency

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome - BioInformant

NIH’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome BioInformant

Phase II COVID-19 placenta cellular therapy trial to launch in Israel - The Jerusalem Post

Phase II COVID-19 placenta cellular therapy trial to launch in Israel The Jerusalem Post

FDA approves Israel-developed stem cell ‘factory’ for research - The Times of Israel

FDA approves Israel-developed stem cell ‘factory’ for research The Times of Israel

Pluristem Prices Firm Commitment Underwritten Public Offering Of 8 Mln. Units - RTTNews

Pluristem Prices Firm Commitment Underwritten Public Offering Of 8 Mln. Units RTTNews

The Abraham Accords and Israel–UAE normalization | 05 The economic dimension - Chatham House

The Abraham Accords and Israel–UAE normalization | 05 The economic dimension Chatham House

Pluristem, United Therapeutics Ink Exclusive Out-license Deal - Quick Facts - RTTNews

Pluristem, United Therapeutics Ink Exclusive Out-license Deal - Quick Facts RTTNews

Cathie Wood’s ARK Invest Sells 194,000 Shares of Pluristem Therapeutics - 24/7 Wall St.

Cathie Wood’s ARK Invest Sells 194,000 Shares of Pluristem Therapeutics 24/7 Wall St.

Pluristem Therapeutics appointed to Stem Cell Partnering Series Advisory Board - quick facts - RTTNews

Pluristem Therapeutics appointed to Stem Cell Partnering Series Advisory Board - quick facts RTTNews

N.J. hospital is 1st in U.S to try placenta therapy on critically ill coronavirus patient - NJ.com

N.J. hospital is 1st in U.S to try placenta therapy on critically ill coronavirus patient NJ.com

Pluristem Therapeutics obtains approval from Biotec Services for PLX-PAD - Quick Facts - RTTNews

Pluristem Therapeutics obtains approval from Biotec Services for PLX-PAD - Quick Facts RTTNews

Pluristem Therapeutics Announces First Patient Enrollment In Phase I Trial To Treat Peripheral Artery Disease With PLX-PAD - RTTNews

Pluristem Therapeutics Announces First Patient Enrollment In Phase I Trial To Treat Peripheral Artery Disease With PLX-PAD RTTNews

Pluristem Files Patent Application for PLX-1 - Technology Networks

Pluristem Files Patent Application for PLX-1 Technology Networks

Study: Placenta cells could reverse stroke damage - The Times of Israel

Study: Placenta cells could reverse stroke damage The Times of Israel

Pluristem gets positive results from radiation treatment trials - The Fiji Times

Pluristem gets positive results from radiation treatment trials The Fiji Times

Top Pluri Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant